Brokerages forecast that Adaptimmune Therapeutics PLC (NASDAQ:ADAP) will report $3.14 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Adaptimmune Therapeutics PLC’s earnings, with the highest sales estimate coming in at $3.50 million and the lowest estimate coming in at $2.92 million. Adaptimmune Therapeutics PLC reported sales of $2.42 million in the same quarter last year, which would suggest a positive year over year growth rate of 29.8%. The business is expected to issue its next quarterly earnings report on Thursday, November 9th.

According to Zacks, analysts expect that Adaptimmune Therapeutics PLC will report full-year sales of $3.14 million for the current year, with estimates ranging from $12.21 million to $15.00 million. For the next financial year, analysts anticipate that the firm will post sales of $17.42 million per share, with estimates ranging from $11.67 million to $30.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Adaptimmune Therapeutics PLC.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.24) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.24). The firm had revenue of $3.52 million during the quarter, compared to analyst estimates of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%.

Several equities research analysts recently commented on ADAP shares. Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Wednesday, July 12th. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Sunday, July 16th. Leerink Swann reaffirmed an “outperform” rating and set a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a report on Friday. Finally, ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $12.08.

Several institutional investors have recently added to or reduced their stakes in the company. Matrix Capital Management Company LP acquired a new position in shares of Adaptimmune Therapeutics PLC during the 2nd quarter valued at about $39,027,000. Balyasny Asset Management LLC acquired a new position in shares of Adaptimmune Therapeutics PLC during the 2nd quarter valued at about $846,000. OxFORD Asset Management LLP acquired a new position in shares of Adaptimmune Therapeutics PLC during the 2nd quarter valued at about $156,000. Virtu KCG Holdings LLC boosted its position in shares of Adaptimmune Therapeutics PLC by 108.0% during the 2nd quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 26,105 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Adaptimmune Therapeutics PLC during the 2nd quarter valued at about $242,000. 68.01% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/10/analysts-anticipate-adaptimmune-therapeutics-plc-adap-will-announce-quarterly-sales-of-3-14-million.html.

Shares of Adaptimmune Therapeutics PLC (ADAP) opened at 8.93 on Friday. Adaptimmune Therapeutics PLC has a 1-year low of $3.76 and a 1-year high of $8.95. The firm has a 50-day moving average of $5.70 and a 200 day moving average of $5.18. The stock’s market cap is $835.12 million.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Get a free copy of the Zacks research report on Adaptimmune Therapeutics PLC (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.